Melanotan I

Overview

Melanotan I, known by its International Nonproprietary Name afamelanotide and the brand name Scenesse, is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH). Unlike most peptides documented on this site, it is an approved prescription medicine. It was authorized by the European Medicines Agency (EMA) under exceptional circumstances on 22 December 2014, and by the U.S. Food and Drug Administration (FDA) on 8 October 2019.

Its single approved indication is the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP), a rare inherited disorder of heme biosynthesis in which exposure to sunlight or even bright artificial light causes severe, debilitating skin pain. The FDA framed the indication as increasing pain-free light exposure in adults with a history of phototoxic reactions from EPP.

Because afamelanotide stimulates the skin's own protective pigment (eumelanin) through the melanocortin system, it is sometimes grouped with cosmetic "tanning peptides." That association is misleading: although increased pigmentation is part of how it works, the molecule earned regulatory approval as a photoprotective therapy for a painful medical condition, evaluated for that purpose alone.

Chemistry and structure

Afamelanotide is a synthetic 13-amino-acid peptide (tridecapeptide) based on the sequence of native alpha-MSH. It differs from the natural hormone by two substitutions designed to increase potency and metabolic stability: norleucine (Nle) replaces methionine at position 4, and D-phenylalanine (D-Phe) replaces L-phenylalanine at position 7. These changes give rise to its chemical shorthand, [Nle4-D-Phe7]-alpha-MSH, also written NDP-MSH or NDP-alpha-MSH. The substitutions slow enzymatic breakdown and substantially raise receptor potency relative to native alpha-MSH.

The free peptide is cleared quickly from plasma, but the approved product is a slow-release implant: a small rod inserted under the skin (above the anterior supra-iliac crest) that delivers afamelanotide over the following days, with re-dosing roughly every two months during periods of higher light exposure.

Mechanism of action

Afamelanotide is an agonist at melanocortin receptors, with strong selectivity for the melanocortin-1 receptor (MC1R) expressed on melanocytes. Activating MC1R increases the synthesis of eumelanin, the darker, more photoprotective form of melanin. This occurs independently of UV exposure: afamelanotide drives pigmentation through receptor signaling rather than requiring sun or tanning-bed light to trigger it.

In erythropoietic protoporphyria, reduced activity of the enzyme ferrochelatase causes the light-sensitive molecule protoporphyrin IX (PPIX) to accumulate. When light (including visible light, not just UV) reaches the skin, it can react with PPIX to generate reactive oxygen species, producing intense pain, redness, and swelling. By increasing eumelanin in the epidermis, afamelanotide raises the skin's capacity to absorb and dissipate light, providing a degree of photoprotection that can lengthen the time patients tolerate light before pain begins. Eumelanin also has antioxidant and free-radical-scavenging properties that may contribute to the protective effect.

Approved use and clinical evidence (EPP)

The approval rests primarily on randomized, double-blind, placebo-controlled trials of the 16 mg subcutaneous implant in adults with EPP.

Langendonk et al., NEJM 2015 (pivotal trials). This publication reported two multicenter, randomized, double-blind, placebo-controlled trials: one conducted in the European Union (74 patients) and one in the United States (94 patients). Participants received an afamelanotide implant or placebo every 60 days. Afamelanotide was associated with a longer total duration of pain-free sun/light exposure and with improved quality of life, with an adverse-event profile the investigators considered acceptable. The EU and US studies differed somewhat in design and duration, but both supported a photoprotective benefit.

Regulatory efficacy summary. In the data underpinning the FDA approval, the median number of hours over 180 days spent in direct sunlight (10am–6pm) on days with no pain was greater for afamelanotide than placebo (reported as roughly 64 hours versus 41 hours). The clinical benefit is therefore framed as more time tolerated in light without pain, rather than a cure for the underlying enzyme deficiency.

Post-authorisation evidence. Because EPP is rare, the EMA approved Scenesse under exceptional circumstances, with continued post-authorisation safety and effectiveness monitoring (including disease-registry and observational cohort studies). Longer-term observational data, for example a German cohort study of afamelanotide 16 mg, have been collected to characterize real-world safety and effectiveness over repeated dosing.

Safety and risks

In the trials and post-marketing surveillance, afamelanotide was generally well tolerated, but it is not without effects. The most commonly reported adverse effects include:

• Implant-site reactions: discoloration, pain, redness, or other local reactions at the insertion site.
• Nausea and headache.
• Fatigue, dizziness, flushing, and somnolence in some patients.

Across the EU labeling, reactions such as nausea, headache, and implant-site effects were reported in roughly 1 in 5 patients and were generally mild.

Skin monitoring. Because afamelanotide darkens the skin and can affect the appearance of moles (nevi), the prescribing information emphasizes regular full-body skin examination by a clinician to monitor existing pigmented lesions and detect any skin changes. Patients are advised to continue established photoprotective measures (clothing, avoidance) rather than relying on the implant alone.

Organ-function cautions. Per EU information, the medicine is not recommended in patients with significantly impaired liver or kidney function, and it remains subject to additional (enhanced) safety monitoring.

Regulatory status (EMA and FDA, for EPP)

European Union (EMA — approved):

• On 22 December 2014, the EMA granted a centralized marketing authorization for Scenesse (afamelanotide) for the prevention of phototoxicity in adult patients with EPP.
• The authorization was granted under exceptional circumstances, reflecting the rarity of EPP and the difficulty of generating comprehensive data; it carries obligations for ongoing post-authorisation safety and effectiveness studies.
• The marketing authorization holder is Clinuvel (Clinuvel Europe Limited).

United States (FDA — approved):

• On 8 October 2019, the FDA approved SCENESSE (afamelanotide) implant to increase pain-free light exposure in adults with a history of phototoxic reactions from EPP.
• The approved product is a 16 mg subcutaneous implant, inserted by a trained healthcare professional every two months.

In both jurisdictions, the approval is narrow and disease-specific. There is no approval anywhere for afamelanotide as a cosmetic tanning agent, for general photoaging, or for any indication other than EPP (with limited use in certain related photodermatoses being investigational).

Melanotan I vs Melanotan II (key distinction)

The names are similar and both act on melanocortin receptors, but these are different molecules with very different regulatory standing, and conflating them is a common and consequential error.

Because Melanotan II is not regulated, its purity, identity, and dose cannot be assumed, and several regulators (for example Australia's TGA and others) have warned against tanning products containing "melanotan." The approval and controlled manufacturing that apply to afamelanotide do not extend to Melanotan II.

How it compares

Afamelanotide is unusual among the peptides on this site in that it is a fully approved medicine, but its approval is tightly limited to EPP, a rare disease, and it is delivered as a clinician-administered implant with built-in skin monitoring.

• It is frequently filed mentally alongside cosmetic "tanning peptides," but it is not a cosmetic product. For the broader category context, see the Skin, hair & cosmetic hub.
• Its closest namesake, Melanotan II, shares a mechanism family (melanocortin agonism) but has no regulatory approval, a less selective receptor profile, and a markedly different real-world use and risk pattern.

So while both peptides increase pigmentation through the melanocortin system, only Melanotan I carries a marketing authorization, and only for a specific, monitored, non-cosmetic indication. The evidence and safety oversight behind afamelanotide should not be assumed to transfer to any unapproved melanocortin peptide.

Common misconceptions

---

This article is provided for educational purposes only and is not medical advice. Melanotan I (afamelanotide / Scenesse) is a prescription medicine approved only for erythropoietic protoporphyria and is administered by a qualified healthcare professional, with skin monitoring as part of its approved use. Nothing here should be interpreted as encouragement to obtain or use any melanocortin peptide for cosmetic tanning or any unapproved purpose.